NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.22 +0.02 (+0.38 %)
(As of 05/24/2018 01:55 PM ET)
Previous Close$5.21
Today's Range$5.15 - $5.28
52-Week Range$4.15 - $7.45
Volume1,060 shs
Average Volume74,019 shs
Market Capitalization$208.60 million
P/E Ratio-2.98
Dividend YieldN/A
Beta1.88

About Foamix Pharmaceuticals (NASDAQ:FOMX)

Foamix Pharmaceuticals logoFoamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Receive FOMX News and Ratings via Email

Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FOMX
CUSIPN/A
Phone972-8931-6233

Debt

Debt-to-Equity RatioN/A
Current Ratio4.54
Quick Ratio4.54

Price-To-Earnings

Trailing P/E Ratio-2.98
Forward P/E Ratio-2.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.67 million
Price / Sales57.60
Cash FlowN/A
Price / CashN/A
Book Value$1.09 per share
Price / Book4.79

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-65,710,000.00
Net Margins-2,119.19%
Return on Equity-103.64%
Return on Assets-90.44%

Miscellaneous

Employees75
Outstanding Shares40,500,000

Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

How were Foamix Pharmaceuticals' earnings last quarter?

Foamix Pharmaceuticals (NASDAQ:FOMX) released its quarterly earnings data on Wednesday, February, 28th. The specialty pharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.01. The specialty pharmaceutical company had revenue of $1.04 million for the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative net margin of 2,119.19% and a negative return on equity of 103.64%. View Foamix Pharmaceuticals' Earnings History.

When is Foamix Pharmaceuticals' next earnings date?

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Foamix Pharmaceuticals.

What price target have analysts set for FOMX?

3 brokerages have issued 1 year price objectives for Foamix Pharmaceuticals' stock. Their predictions range from $8.00 to $12.00. On average, they expect Foamix Pharmaceuticals' share price to reach $9.6667 in the next year. View Analyst Ratings for Foamix Pharmaceuticals.

Who are some of Foamix Pharmaceuticals' key competitors?

Who are Foamix Pharmaceuticals' key executives?

Foamix Pharmaceuticals' management team includes the folowing people:
  • Mr. David T. Domzalski, CEO, Director & Pres of Foamix Pharmaceuticals Inc. (Age 51)
  • Mr. Meir Eini, Co-Founder & Innovation Advisor (Age 63)
  • Mr. Ilan Hadar MBA, CFO & Country Mang. (Age 49)
  • Mr. Alvin D. Howard, VP of Regulatory Affairs - Foamix Pharmaceuticals Inc (Age 63)
  • Mr. Yohan Hazot, Chief Technology Officer (Age 35)

Has Foamix Pharmaceuticals been receiving favorable news coverage?

Press coverage about FOMX stock has trended somewhat positive on Thursday, Accern reports. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Foamix Pharmaceuticals earned a news sentiment score of 0.12 on Accern's scale. They also assigned news stories about the specialty pharmaceutical company an impact score of 46.66 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Foamix Pharmaceuticals' major shareholders?

Foamix Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (2.35%), Millennium Management LLC (1.88%), BlackRock Inc. (1.24%), Handelsbanken Fonder AB (0.90%), Handelsbanken Fonder AB (0.90%) and DAFNA Capital Management LLC (0.83%). Company insiders that own Foamix Pharmaceuticals stock include David Domzalski, Meir Eini and Russell P Elliott. View Institutional Ownership Trends for Foamix Pharmaceuticals.

Which major investors are selling Foamix Pharmaceuticals stock?

FOMX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., DAFNA Capital Management LLC, Wells Fargo & Company MN and Opaleye Management Inc.. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include David Domzalski, Meir Eini and Russell P Elliott. View Insider Buying and Selling for Foamix Pharmaceuticals.

Which major investors are buying Foamix Pharmaceuticals stock?

FOMX stock was purchased by a variety of institutional investors in the last quarter, including Eversept Partners LLC, Handelsbanken Fonder AB, Handelsbanken Fonder AB, Sofinnova Ventures Inc, A.R.T. Advisors LLC and Millennium Management LLC. View Insider Buying and Selling for Foamix Pharmaceuticals.

How do I buy shares of Foamix Pharmaceuticals?

Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foamix Pharmaceuticals' stock price today?

One share of FOMX stock can currently be purchased for approximately $5.22.

How big of a company is Foamix Pharmaceuticals?

Foamix Pharmaceuticals has a market capitalization of $208.60 million and generates $3.67 million in revenue each year. The specialty pharmaceutical company earns $-65,710,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Foamix Pharmaceuticals employs 75 workers across the globe.

How can I contact Foamix Pharmaceuticals?

Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]


MarketBeat Community Rating for Foamix Pharmaceuticals (FOMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Foamix Pharmaceuticals (NASDAQ:FOMX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Foamix Pharmaceuticals in the last 12 months. Their average twelve-month price target is $9.6667, suggesting that the stock has a possible upside of 85.19%. The high price target for FOMX is $12.00 and the low price target for FOMX is $8.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.6667$9.6667$9.6667$10.50
Price Target Upside: 85.19% upside77.37% upside45.58% upside131.79% upside

Foamix Pharmaceuticals (NASDAQ:FOMX) Consensus Price Target History

Price Target History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Foamix Pharmaceuticals (NASDAQ:FOMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018HC WainwrightSet Price TargetBuy$12.00LowView Rating Details
12/14/2017GuggenheimReiterated RatingBuy$8.00HighView Rating Details
7/19/2017Credit Suisse GroupReiterated RatingBuy$9.00LowView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Foamix Pharmaceuticals (NASDAQ:FOMX) Earnings History and Estimates Chart

Earnings by Quarter for Foamix Pharmaceuticals (NASDAQ:FOMX)

Foamix Pharmaceuticals (NASDAQ:FOMX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.76 EPS
Next Year EPS Consensus Estimate: $-1.87 EPS

Foamix Pharmaceuticals (NASDAQ FOMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2018        
5/9/2018Q1($0.45)($0.69)$1.11 million$0.91 millionViewN/AView Earnings Details
2/28/2018Q4 2017($0.45)($0.46)$1.10 million$1.04 millionViewN/AView Earnings Details
11/14/2017n/a($0.44)($0.47)$0.90 million$0.90 millionViewN/AView Earnings Details
8/8/2017Q2($0.39)($0.44)$1.50 million$0.80 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.39)$0.93 millionViewN/AView Earnings Details
2/21/2017Q416($0.26)($0.31)$1.49 millionViewN/AView Earnings Details
11/15/2016Q3 2016($0.32)($0.19)$2.54 millionViewN/AView Earnings Details
8/10/2016Q216($0.25)($0.27)$1.10 million$1.50 millionViewListenView Earnings Details
5/10/2016Q1($0.23)($0.15)$0.53 million$0.75 millionViewListenView Earnings Details
3/3/2016Q4 2015($0.21)($0.17)$0.05 million$0.27 millionViewN/AView Earnings Details
11/11/2015Q315($0.20)($0.11)$1.50 million$0.02 millionViewListenView Earnings Details
8/19/2015Q215($0.14)($0.18)$1.00 million$0.11 millionViewListenView Earnings Details
5/12/2015Q1($0.12)($0.14)$1.00 million$0.45 millionViewN/AView Earnings Details
4/15/2015($0.12)($0.18)ViewN/AView Earnings Details
3/18/2015Q4 2014($0.12)($0.18)$5.00 millionViewN/AView Earnings Details
11/14/2014Q314($0.07)($0.12)$1.00 million$0.42 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Foamix Pharmaceuticals (NASDAQ:FOMX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Foamix Pharmaceuticals (NASDAQ FOMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 52.70%
Insider Trading History for Foamix Pharmaceuticals (NASDAQ:FOMX)
Insider Trading History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Foamix Pharmaceuticals (NASDAQ FOMX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018David DomzalskiCEOSell602$5.08$3,058.16139,754View SEC Filing  
4/2/2018Russell P ElliottVPSell142$5.08$721.3612,726View SEC Filing  
3/2/2018Russell P ElliottVPSell817$6.14$5,016.3812,868View SEC Filing  
3/1/2018David DomzalskiCEOSell66$5.95$392.70140,356View SEC Filing  
1/10/2018Meir EiniInsiderSell5,000$6.05$30,250.0016,271View SEC Filing  
1/8/2018Meir EiniInsiderSell5,000$6.17$30,850.0016,271View SEC Filing  
1/4/2018Meir EiniInsiderSell5,000$6.68$33,400.0016,271View SEC Filing  
1/2/2018Meir EiniInsiderSell5,000$6.18$30,900.0016,271View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Foamix Pharmaceuticals (NASDAQ FOMX) News Headlines

Source:
DateHeadline
Comparing Foamix Pharmaceuticals (FOMX) and ChromaDex (CDXC)Comparing Foamix Pharmaceuticals (FOMX) and ChromaDex (CDXC)
www.americanbankingnews.com - May 19 at 7:18 PM
Foamix Pharmaceuticals (FOMX) Stock Rating Upgraded by ValuEngineFoamix Pharmaceuticals (FOMX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM
Edited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMTEdited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:53 AM
Foamix Pharmaceuticals (FOMX) Releases Quarterly  Earnings Results, Misses Estimates By $0.29 EPSFoamix Pharmaceuticals (FOMX) Releases Quarterly Earnings Results, Misses Estimates By $0.29 EPS
www.americanbankingnews.com - May 9 at 9:32 PM
Foamix Pharmaceuticals (FOMX) CEO Dave Domzalski on Q1 2018 Results - Earnings Call TranscriptFoamix Pharmaceuticals' (FOMX) CEO Dave Domzalski on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:08 PM
Foamix Pharmaceuticals misses by $0.24, misses on revenueFoamix Pharmaceuticals misses by $0.24, misses on revenue
seekingalpha.com - May 9 at 8:49 AM
Foamix: 1Q Earnings SnapshotFoamix: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:49 AM
With A -124.01% Earnings Drop, Did Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Really Underperform?With A -124.01% Earnings Drop, Did Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Really Underperform?
finance.yahoo.com - May 9 at 8:49 AM
Foamix Reports First Quarter 2018 Financial Results and Provides Corporate UpdateFoamix Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 8 at 5:09 PM
Foamix Pharmaceuticals (FOMX) Given a $12.00 Price Target at HC WainwrightFoamix Pharmaceuticals (FOMX) Given a $12.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 8 at 2:28 PM
Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
finance.yahoo.com - May 7 at 8:43 AM
Foamix Pharmaceuticals (FOMX) Downgraded by Zacks Investment ResearchFoamix Pharmaceuticals (FOMX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 4 at 1:57 PM
Foamix Pharmaceuticals (FOMX) Scheduled to Post Quarterly Earnings on WednesdayFoamix Pharmaceuticals (FOMX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 2:32 AM
Reviewing Foamix Pharmaceuticals (FOMX) & USANA Health Sciences (USNA)Reviewing Foamix Pharmaceuticals (FOMX) & USANA Health Sciences (USNA)
www.americanbankingnews.com - April 29 at 7:56 AM
Head-To-Head Review: Foamix Pharmaceuticals (FOMX) versus Actelion (ALIOF)Head-To-Head Review: Foamix Pharmaceuticals (FOMX) versus Actelion (ALIOF)
www.americanbankingnews.com - April 28 at 3:06 AM
Foamix Pharmaceuticals (FOMX) versus USANA Health Sciences (USNA) Head to Head ContrastFoamix Pharmaceuticals (FOMX) versus USANA Health Sciences (USNA) Head to Head Contrast
www.americanbankingnews.com - April 20 at 5:25 AM
Critical Survey: Foamix Pharmaceuticals (FOMX) and MediWound (MDWD)Critical Survey: Foamix Pharmaceuticals (FOMX) and MediWound (MDWD)
www.americanbankingnews.com - April 19 at 9:06 PM
Foamix Pharmaceuticals (FOMX) Given a $12.00 Price Target by HC Wainwright AnalystsFoamix Pharmaceuticals (FOMX) Given a $12.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 18 at 8:36 AM
Foamix Announces $16 Million Investment by OrbiMedFoamix Announces $16 Million Investment by OrbiMed
finance.yahoo.com - April 16 at 8:42 AM
Reviewing Actelion (ALIOF) & Foamix Pharmaceuticals (FOMX)Reviewing Actelion (ALIOF) & Foamix Pharmaceuticals (FOMX)
www.americanbankingnews.com - April 11 at 5:35 AM
MediWound (MDWD) & Foamix Pharmaceuticals (FOMX) Head to Head ComparisonMediWound (MDWD) & Foamix Pharmaceuticals (FOMX) Head to Head Comparison
www.americanbankingnews.com - April 11 at 3:17 AM
Foamix Pharmaceuticals (FOMX) Cut to Sell at Zacks Investment ResearchFoamix Pharmaceuticals (FOMX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 8 at 12:40 AM
Analyzing Actelion (ALIOF) & Foamix Pharmaceuticals (FOMX)Analyzing Actelion (ALIOF) & Foamix Pharmaceuticals (FOMX)
www.americanbankingnews.com - April 3 at 9:20 PM
Foamix Pharmaceuticals (FOMX) Upgraded at ValuEngineFoamix Pharmaceuticals (FOMX) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 3:35 PM
Head-To-Head Comparison: Stada Arzneimittel (STDAF) versus Foamix Pharmaceuticals (FOMX)Head-To-Head Comparison: Stada Arzneimittel (STDAF) versus Foamix Pharmaceuticals (FOMX)
www.americanbankingnews.com - April 2 at 1:50 AM
Foamix Pharmaceuticals (FOMX) Upgraded to Sell by ValuEngineFoamix Pharmaceuticals (FOMX) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - March 23 at 11:22 PM
Foamix Pharmaceuticals Target of Unusually Large Options Trading (FOMX)Foamix Pharmaceuticals Target of Unusually Large Options Trading (FOMX)
www.americanbankingnews.com - March 20 at 6:40 AM
Cheniere Energy Partners Holdings And Other Great Growth StocksCheniere Energy Partners Holdings And Other Great Growth Stocks
finance.yahoo.com - March 12 at 12:17 PM
Foamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care ConferenceFoamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:42 AM
Senzar Asset Management LLC Sells 85,900 Shares of Foamix Pharmaceuticals Ltd (FOMX)Senzar Asset Management LLC Sells 85,900 Shares of Foamix Pharmaceuticals Ltd (FOMX)
www.americanbankingnews.com - March 5 at 3:44 PM
Foamix Pharmaceuticals Ltd (FOMX) Stake Increased by Ascend Capital LLCFoamix Pharmaceuticals Ltd (FOMX) Stake Increased by Ascend Capital LLC
www.americanbankingnews.com - March 2 at 5:06 AM
Foamix Pharmaceuticals (FOMX) Rating Lowered to Sell at Zacks Investment ResearchFoamix Pharmaceuticals (FOMX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 2 at 12:42 AM
Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate UpdateFoamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - February 28 at 8:44 AM
When Will Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Become Profitable?When Will Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Become Profitable?
finance.yahoo.com - February 27 at 8:48 AM
Microbot Medical (MBOT) vs. Foamix Pharmaceuticals (FOMX) Critical ComparisonMicrobot Medical (MBOT) vs. Foamix Pharmaceuticals (FOMX) Critical Comparison
www.americanbankingnews.com - February 17 at 7:32 PM
BRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix PharmaceuticalsBRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals
www.reuters.com - February 14 at 9:36 AM
Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28
finance.yahoo.com - February 13 at 9:44 AM
Foamix Pharmaceuticals (FOMX) Set to Announce Quarterly Earnings on MondayFoamix Pharmaceuticals (FOMX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - February 12 at 3:02 AM
Traders Purchase High Volume of Put Options on Foamix Pharmaceuticals (FOMX)Traders Purchase High Volume of Put Options on Foamix Pharmaceuticals (FOMX)
www.americanbankingnews.com - January 25 at 1:52 AM
Meir Eini Sells 5,000 Shares of Foamix Pharmaceuticals Ltd (FOMX) StockMeir Eini Sells 5,000 Shares of Foamix Pharmaceuticals Ltd (FOMX) Stock
www.americanbankingnews.com - January 18 at 8:30 PM
Foamix Pharmaceuticals Ltd (FOMX) Insider Sells $30,900.00 in StockFoamix Pharmaceuticals Ltd (FOMX) Insider Sells $30,900.00 in Stock
www.americanbankingnews.com - January 18 at 8:30 PM
Foamix Pharmaceuticals Ltd (FOMX) Insider Meir Eini Sells 5,000 SharesFoamix Pharmaceuticals Ltd (FOMX) Insider Meir Eini Sells 5,000 Shares
www.americanbankingnews.com - January 18 at 8:30 PM
Foamix Pharmaceuticals (FOMX) PT Set at $12.00 by HC WainwrightFoamix Pharmaceuticals (FOMX) PT Set at $12.00 by HC Wainwright
www.americanbankingnews.com - January 5 at 8:44 PM
Foamix (FOMX) Reports Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 YearFoamix (FOMX) Reports Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
www.streetinsider.com - January 5 at 10:09 AM
Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 YearFoamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 Year
finance.yahoo.com - January 4 at 9:58 AM
Foamix Names Mr. David Domzalski as a Member of the Board of Foamix PharmaceuticalsFoamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals
finance.yahoo.com - January 3 at 9:22 AM
Foamix Pharmaceuticals (FOMX) Stock Rating Reaffirmed by GuggenheimFoamix Pharmaceuticals (FOMX) Stock Rating Reaffirmed by Guggenheim
www.americanbankingnews.com - December 15 at 1:36 PM
Foamix Pharmaceuticals (FOMX) and Its Rivals Head-To-Head AnalysisFoamix Pharmaceuticals (FOMX) and Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - December 7 at 5:30 AM
Guggenheim Initiates Coverage on Foamix Pharmaceuticals (FOMX)Guggenheim Initiates Coverage on Foamix Pharmaceuticals (FOMX)
www.americanbankingnews.com - December 5 at 8:48 PM
Foamix Pharmaceuticals (FOMX) Lifted to "Hold" at Zacks Investment ResearchFoamix Pharmaceuticals (FOMX) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 29 at 8:54 PM

SEC Filings

Foamix Pharmaceuticals (NASDAQ:FOMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Foamix Pharmaceuticals (NASDAQ:FOMX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Foamix Pharmaceuticals (NASDAQ FOMX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.